Cancer Network spoke with Steven H. Lin, MD, PhD, of MD Anderson Cancer Center, on the findings of a phase II trial of atezolizumab plus chemoradiation therapy in locally advanced non-small-cell lung cancer.
Cancer Network spoke with Steven H. Lin, MD, PhD, associate professor and radiation oncologist at The University of Texas MD Anderson Cancer Center, on the findings of a phase II trial (abstract 8512) combining atezolizumab with chemoradiation therapy in locally advanced non-small-cell lung cancer. The results were presented at ASCO 2019 in Chicago.
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.